nach oben

Clinical Oral Investigations

Erschienen in:

01.05.2024 | Research

Time-course of pain and salivary opiorphin release in response to oral capsaicin differ in burning mouth syndrome patients, temporomandibular disorders patients and control subjects

verfasst von: Iva Z. Alajbeg, Ema Vrbanovic, Ivan Alajbeg, Ivan Orabovic, Klara Naka, Antonija Mrla, Yves Boucher

Erschienen in: Clinical Oral Investigations | Ausgabe 5/2024

Einloggen, um Zugang zu erhalten

Abstract

Objectives

Opiorphin is an analgesic peptide released by salivary glands and capsaicin an agonist of TRPV1 receptors eliciting burning sensations. The primary objective of this study was to assess opiorphin release after stimulation of the tongue by capsaicin (STC). The secondary objectives were to compare opiorphin release after STC in 3 groups of subjects [healthy (CTRL), Burning Mouth Syndrome (BMS), painful Temporomandibular disorders (TMDp)] and pain evoked by STC in these 3 groups.

Materials and methods

Salivary opiorphin was assessed with high-performance liquid chromatography at 3 different time points (baseline, after 5 min and 20 min of STC). Pain was self-reported on a (0–10) numeric rating scale.

Results

Three groups (N = 16) of adults were recruited at the Clinical Hospital Centre and School of Dental Medicine in Zagreb. Opiorphin levels were higher (1) in TMDp compared to CTRL in 1st (2.23 ± 1.72 pg/ul vs. 0.67 ± 0.44 pg/ul, p = 0.002) and 3rd sampling (2.44 ± 2.01 pg/ul vs. 0.74 ± 0.52 pg/ul, p = 0.020) and (2) within BMS group at 3rd sampling vs. baseline (p < 0.025). Pain scores were higher in BMS compared to TMDp (p < 0.025) and CTRL (p < 0.025).

Conclusion

This study evidenced (1) a differential basal amount of opiorphin in two pain conditions and control subjects (2) a differential kinetic of release of opiorphin after STC in CTRL, BMS and TMDp (3) a differential pain perception after STC in BMS and TMDp vs. CTRL, which can provide a readout for animal models.

Clinical relevance

The specific regulation of opiorphin release in patients with orofacial painful conditions provides valuable insights for clinicians and researchers in physiology and pathology and encourages further research in this area.

Trial registration

ClinicalTrials.gov NCT04694274. Registered on 01/05/2021.

Nur mit Berechtigung zugänglich

Craig AD (2003) A new view of pain as a homeostatic emotion. Trends Neurosci 26(6):303–307. https://doi.org/10.1016/s0166-2236(03)00123-1CrossRefPubMed

Donnelly CR, Chen O, Ji RR (2020) How do sensory neurons sense Danger signals? Trends Neurosci 43(10):822–838. https://doi.org/10.1016/j.tins.2020.07.008CrossRefPubMedPubMedCentral

Green BG (2012) Chemesthesis and the chemical senses as components of a chemofensor complex. Chem Senses 37(3):201–206. https://doi.org/10.1093/chemse/bjr119CrossRefPubMed

Houghton JW, Carpenter G, Hans J, Pesaro M, Lynham S, Proctor G (2020) Agonists of orally expressed TRP channels stimulate salivary secretion and modify the salivary proteome. Mol Cell Proteomics: MCP 19(10):1664–1676. https://doi.org/10.1074/mcp.RA120.002174CrossRefPubMedPubMedCentral

Roper SD (2014) TRPs in taste and chemesthesis. Handb Exp Pharmacol 223:827–871. https://doi.org/10.1007/978-3-319-05161-1_5CrossRefPubMedPubMedCentral

Simon SA, Gutierrez R (2017) TRP Channels at the Periphery of the Taste and Trigeminal Systems. In: Emir TLR, editor. Neurobiology of TRP Channels. Boca Raton (FL): CRC Press/Taylor & Francis [cited 2020 Oct 8]. (Frontiers in Neuroscience). http://www.ncbi.nlm.nih.gov/books/NBK476105/

Kichko TI, Neuhuber W, Kobal G, Reeh PW (2018) The roles of TRPV1, TRPA1 and TRPM8 channels in chemical and thermal sensitivity of the mouse oral mucosa. Eur J Neurosci 47(3):201–210. https://doi.org/10.1111/ejn.13799CrossRefPubMed

Slack JP (2016) Molecular Pharmacology of Chemesthesis - ScienceDirect [cited 2020 Oct 8]. https://www.sciencedirect.com/science/article/pii/B9780128016947000214

Arendt-Nielsen L, Carstens E, Proctor G, Boucher Y, Clavé P, Albin Nielsen K, Nielsen TA, Reeh PW (2022) The role of TRP Channels in Nicotinic provoked Pain and Irritation from the oral cavity and Throat: translating Animal Data to humans. Nicotine Tob Res 24(12):1849–1860. https://doi.org/10.1093/ntr/ntac054CrossRefPubMedPubMedCentral

10.

Simons CT, Klein AH, Carstens E (2019) Chemogenic subqualities of Mouthfeel. Chem Senses 44(5):281–288. https://doi.org/10.1093/chemse/bjz016CrossRefPubMedPubMedCentral

11.

Boudreau SA, Wang K, Svensson P, Sessle BJ, Arendt-Nielsen L (2009) Vascular and psychophysical effects of topical capsaicin application to orofacial tissues. J Orofac Pain 23(3):253–264PubMedPubMedCentral

12.

Gazerani P, Andersen OK, Arendt-Nielsen L (2007) Site-specific, dose-dependent, and sex-related responses to the experimental pain model induced by intradermal injection of capsaicin to the foreheads and forearms of healthy humans. J Orofac Pain 21(4):289–302PubMed

13.

Rougeot C, Rosinski-Chupin I, Mathison R, Rougeon F (2000) Rodent submandibular gland peptide hormones and other biologically active peptides. Peptides 21(3):443–455. https://doi.org/10.1016/S0196-9781(00)00158-3CrossRefPubMed

14.

Wisner A, Dufour E, Messaoudi M, Nejdi A, Marcel A, Ungeheuer MN et al (2006) Human opiorphin, a natural antinociceptive modulator of opioid-dependent pathways. Proc Natl Acad Sci USA 21(47):17979–17984. https://doi.org/10.1073/pnas.0605865103CrossRef

15.

Rosa M, Arsequell G, Rougeot C, Calle LP, Marcelo F, Pinto M et al (2012) Structure-activity relationship study of opiorphin, a human dual ectopeptidase inhibitor with antinociceptive properties. J Med Chem 9(3):1181–1188. https://doi.org/10.1021/jm2012112CrossRef

16.

Sitbon P, Van Elstraete A, Hamdi L, Juarez-Perez V, Mazoit JX, Benhamou D et al (2016) STR-324, a stable Analog of Opiorphin, causes Analgesia in Postoperative Pain by activating endogenous opioid receptor-dependent pathways. Anesthesiology 125(5):1017–1029. https://doi.org/10.1097/ALN.0000000000001320CrossRefPubMed

17.

Van Elstraete A, Sitbon P, Hamdi L, Juarez-Perez V, Mazoit JX, Benhamou D et al (2018) The Opiorphin Analog STR-324 decreases sensory hypersensitivity in a rat model of Neuropathic Pain. Anesth Analg 126(6):2102–2111. https://doi.org/10.1213/ANE.0000000000002413CrossRefPubMed

18.

Luo P, Li X, Gao Y, Chen Z, Zhang Q, Wang Z et al (2022) Central administration of human opiorphin alleviates dextran sodium sulfate-induced colitis in mice through activation of the endogenous opioid system. Front Pharmacol 13:904926. https://doi.org/10.3389/fphar.2022.904926CrossRefPubMedPubMedCentral

19.

Porporatti AL, Oliveira Machado AA, Alajbeg I, Alajbeg IZ, Paszynka E, Dmitrzak-Weglarz M et al (2022) Opiorphin as a biomarker of orofacial conditions: a meta-analysis. Sci Rep 13(1):15533. https://doi.org/10.1038/s41598-023-42051-y

20.

Zlendić M, Vrbanović E, Tomljanović M, Gall Trošelj K, Đerfi KV, Alajbeg IZ (2023) Association of oral behaviours and psychological factors with selected genotypes in pain-related TMD. Oral Dis. https://doi.org/10.1111/odi.14583CrossRefPubMed

21.

Vandenbroucke JP, Elm E, Altman DG, Gøtzsche PC, Mulrow CD, Pocock SJ et al (2014) Strengthening the reporting of Observational studies in Epidemiology (STROBE): explanation and elaboration. Int J Surg 12(12):1500–1524. https://doi.org/10.1016/j.ijsu.2014.07.014CrossRefPubMed

22.

Haefeli M, Elfering A (2006) Pain assessment. Eur Spine J 15(Suppl 1):S17–24. https://doi.org/10.1007/s00586-005-1044-xCrossRefPubMed

23.

Schiffman E, Ohrbach R, Truelove E, Look J, Anderson G, Goulet JP et al (2014) Diagnostic criteria for Temporomandibular disorders (DC/TMD) for clinical and Research Applications: recommendations of the International RDC/TMD Consortium Network* and Orofacial Pain Special Interest Group†. J Oral Facial Pain Headache 28(1):6–27. https://doi.org/10.11607/jop.1151CrossRefPubMed

24.

Salarić I, Sabalić M, Alajbeg I (2017) Opiorphin in burning mouth syndrome patients: a case-control study. Clin Oral Investig 21(7):2363–2370. https://doi.org/10.1007/s00784-016-2031-9CrossRefPubMed

25.

Ngom PI, Dubray C, Woda A, Dallel R (2001) A human oral capsaicin pain model to assess topical anesthetic-analgesic drugs. Neurosci Lett 28(3):149–152. https://doi.org/10.1016/s0304-3940(01)02401-6CrossRef

26.

Dessirier JM, O’Mahony M, Sieffermann JM, Carstens E (1998) Mecamylamine inhibits nicotine but not capsaicin irritation on the tongue: psychophysical evidence that nicotine and capsaicin activate separate molecular receptors. Neurosci Lett 9(2):65–68. https://doi.org/10.1016/s0304-3940(97)00930-0CrossRef

27.

Brkljačić L, Sabalić M, Salarić I, Jerić I, Alajbeg I, Nemet I (2011) Development and validation of a liquid chromatography-tandem mass spectrometry method for the quantification of opiorphin in human saliva. J Chromatogr B Analyt Technol Biomed Life Sci 15(32):3920–3926. https://doi.org/10.1016/j.jchromb.2011.11.003CrossRef

28.

Boucher Y, Braud A, Dufour E, Agbo-Godeau S, Baaroun V, Descroix V et al (2016) Opiorphin levels in fluids of burning mouth syndrome patients: a case-control study. Clin Oral Investig 21(7):2157–2164. https://doi.org/10.1007/s00784-016-1991-0CrossRefPubMed

29.

Ruangsri S, Jorns TP, Chaiyarit P (2019) Opiorphin Level in Unstimulated Whole Saliva of Burning Mouth Syndrome Patients. Journal of the medical association of Thailand 102(4):63

30.

Hu X, Ayed C, Chen J, Fisk I, Yang N (2022) The role of capsaicin stimulation on the physicochemical properties of saliva and aroma release in model aqueous and oil systems. Food Chem 30:386:132824. https://doi.org/10.1016/j.foodchem.2022.132824CrossRef

31.

Cairns BE (2010) Pathophysiology of TMD pain–basic mechanisms and their implications for pharmacotherapy. J Oral Rehabil 37(6):391–410. https://doi.org/10.1111/j.1365-2842.2010.02074.xCrossRefPubMed

32.

Kolkka M, Forssell H, Virtanen A, Puhakka A, Pesonen U, Jääskeläinen SK (2019) Neurophysiology and genetics of burning mouth syndrome. Eur J Pain 23(6):1153–1161. https://doi.org/10.1002/ejp.1382CrossRefPubMed

33.

Mendak-Ziółko M, Konopka T, Bogucki ZA (2012) Evaluation of select neurophysiological, clinical and psychological tests for burning mouth syndrome. Oral Surg Oral Med Oral Pathol Oral Radiol 114(3):325–332. https://doi.org/10.1016/j.oooo.2012.04.004CrossRefPubMed

34.

Cairns BE (2022) The contribution of autonomic mechanisms to pain in temporomandibular disorders: a narrative review. J Oral Rehabil 49(11):1115–1126. https://doi.org/10.1111/joor.13370CrossRefPubMed

35.

Javelot H, Messaoudi M, Garnier S, Rougeot C (2010) Human opiorphin is a naturally occurring antidepressant acting selectively on enkephalin-dependent delta-opioid pathways. J Physiol Pharmacology: Official J Pol Physiological Soc 61(3):355–362

36.

Maraschin JC, Rangel MP, Bonfim AJ, Kitayama M, Graeff FG, Zangrossi H et al (2016) Opiorphin causes a panicolytic-like effect in rat panic models mediated by µ-opioid receptors in the dorsal periaqueductal gray. Neuropharmacology 101:264–270. https://doi.org/10.1016/j.neuropharm.2015.09.008CrossRefPubMed

37.

Mokhtar M, Singh P (2022) Neuroanatomy, Periaqueductal Gray. In: StatPearls. StatPearls Publishing; [cited 2023 May 16]. https://www.ncbi.nlm.nih.gov/books/NBK554391/

38.

Yang QZ, Lu SS, Tian XZ, Yang AM, Ge WW, Chen Q (2011) The antidepressant-like effect of human opiorphin via opioid-dependent pathways in mice. Neurosci Lett 489(2):131–135. https://doi.org/10.1016/j.neulet.2010.12.002CrossRefPubMed

39.

Sestile CC, Maraschin JC, Rangel MP, Santana RG, Zangrossi H, Graeff FG et al (2017) B2-kinin receptors in the dorsal periaqueductal gray are implicated in the panicolytic-like effect of opiorphin. Prog Neuropsychopharmacol Biol Psychiatry 79(Pt B):493–498CrossRefPubMed

40.

Slade GD, Ohrbach R, Greenspan JD, Fillingim RB, Bair E, Sanders AE et al (2016) Painful temporomandibular disorder: Decade of Discovery from OPPERA studies. J Dent Res 95(10):1084–1092. https://doi.org/10.1177/0022034516653743CrossRefPubMedPubMedCentral

41.

Jääskeläinen SK (2018) Is burning mouth syndrome a neuropathic pain condition? Pain 159(3):610–613. https://doi.org/10.1097/j.pain.0000000000001090CrossRefPubMed

42.

Porporatti AL, Schroder ÂGD, Lebel A et al (2023) Is burning mouth syndrome associated with stress? A meta-analysis. J Rehabil. https://doi.org/10.1111/joor.13536CrossRef

43.

Ozdogan S, Sonmez C, Yolcu D, Gungormus M (2020) Tear Opiorphin levels in Ocular Pain caused by corneal foreign body. Cornea 39(11):1377–1380. https://doi.org/10.1097/ICO.0000000000002383CrossRefPubMed

44.

Grushka M (1987) Clinical features of burning mouth syndrome. Oral Surg Oral Med Oral Pathol 63(1):30–36. https://doi.org/10.1016/0030-4220(87)90336-7CrossRefPubMed

45.

Forssell H, Jääskeläinen S, Tenovuo O, Hinkka S (2002) Sensory dysfunction in burning mouth syndrome. Pain 99(1–2):41–47. https://doi.org/10.1016/s0304-3959(02)00052 – 0CrossRefPubMed

46.

Lauria G, Majorana A, Borgna M, Lombardi R, Penza P, Padovani A et al (2005) Trigeminal small-fiber sensory neuropathy causes burning mouth syndrome. Pain 115(3):332–337. https://doi.org/10.1016/j.pain.2005.03.028CrossRefPubMed

47.

Simons CT, Carstens E (2020) 3.20 - Oral Chemesthesis and Taste. In: Fritzsch B, editor. The Senses: A Comprehensive Reference (Second Edition). Oxford: Elsevier; [cited 2023 May 18]. pp. 398–422. https://www.sciencedirect.com/science/article/pii/B9780128093245241382

48.

Silvestre FJ, Silvestre-Rangil J, Tamarit-Santafé C, Bautista D (2012) Application of a capsaicin rinse in the treatment of burning mouth syndrome. Med Oral Patol Oral Cir Bucal 17(1):e1–4. https://doi.org/10.4317/medoral.17219CrossRefPubMed

49.

Jørgensen MR, Pedersen AML (2017) Analgesic effect of topical oral capsaicin gel in burning mouth syndrome. Acta Odontol Scand 75(2):130–136. https://doi.org/10.1080/00016357.2016.1269191CrossRefPubMed

50.

Winocur E, Gavish A, Halachmi M, Eli I, Gazit E (2000) Topical application of capsaicin for the treatment of localized pain in the temporomandibular joint area. J Orofac Pain 14(1):31–36PubMed

51.

Campbell BK, Fillingim RB, Lee S, Brao R, Price DD, Neubert JK (2017) Effects of High-Dose Capsaicin on TMD subjects: a Randomized Clinical Study. JDR Clin Trans Res 2(1):58–65. https://doi.org/10.1177/2380084416675837CrossRefPubMed

52.

Baad-Hansen L, List T, Kaube H, Jensen TS, Svensson P (2006) Blink reflexes in patients with atypical odontalgia and matched healthy controls. Exp Brain Res 172(4):498–506. https://doi.org/10.1007/s00221-006-0358-1CrossRefPubMed

53.

Boucher Y, Carstens MI, Sawyer CM, Zanotto KL, Merrill AW, Carstens E (2013) Capsaicin avoidance as a measure of chemical hyperalgesia in orofacial nerve injury models. Neurosci Lett 24543:37–49. https://doi.org/10.1016/j.neulet.2013.02.060CrossRef

54.

Boucher Y, Simons CT, Carstens MI, Carstens E (2014) Effects of gustatory nerve transection and/or ovariectomy on oral capsaicin avoidance in rats. Pain 155(4):814–820. https://doi.org/10.1016/j.pain.2014.01.020CrossRefPubMedPubMedCentral

55.

Yilmaz Z, Renton T, Yiangou Y, Zakrzewska J, Chessell IP, Bountra C et al (2007) Burning mouth syndrome as a trigeminal small fibre neuropathy: increased heat and capsaicin receptor TRPV1 in nerve fibres correlates with pain score. J Clin Neurosci 14(9):864–871. https://doi.org/10.1016/j.jocn.2006.09.002CrossRefPubMed

56.

Just T, Steiner S, Pau HW Oral pain perception and taste in burning mouth syndrome (2010). J Oral Pathol Med 39(1):22–27. https://doi.org/10.1111/j.1600-0714.2009.00824.x

57.

Gremeau-Richard C, Pionchon P, Mulliez A, Dualé C, Dallel R (2022) Enhanced pain facilitation rather than impaired pain inhibition in burning mouth syndrome female patients. J Headache Pain 23(1):143. https://doi.org/10.1186/s10194-022-01516-7CrossRefPubMedPubMedCentral

58.

Grushka M, Sessle BJ, Howley TP (1987) Psychophysical assessment of tactile, pain and thermal sensory functions in burning mouth syndrome. Pain 28(2):169–184 10.1016/0304–3959(87)90114-XCrossRefPubMed

59.

Yang G, Su S, Jie H, Baad-Hansen L, Wang K, Yan S et al (2019) Somatosensory profiling of patients with burning Mouth Syndrome and correlations with psychologic factors. J Oral Facial Pain Headache 33(3):278–286. https://doi.org/10.11607/ofph.2358CrossRefPubMed

60.

Wolowski A, Schwarzbach N, Hörning H (2021) Thermal quantitative sensory testing in burning mouth syndrome. Clin Oral Investig 25(5):3059–3066. https://doi.org/10.1007/s00784-020-03626-5CrossRefPubMed

61.

Ozasa K, Noma N, Young A, Korczeniewska OA, Eliav E, Imamura Y (2022) Potential differences in somatosensory function during premenopause and early and late postmenopause in patients with burning mouth syndrome: an observational case-control study. J Dent Sci 17(1):399–406. https://doi.org/10.1016/j.jds.2021.08.010CrossRefPubMed

62.

Dufour E, Villard-Saussine S, Mellon V, Leandri R, Jouannet P, Ungeheuer M et al (2013) Opiorphin Secretion Pattern in Healthy Volunteers: Gender Difference and Organ Specificity. Biochemistry & Analytical Biochemistry [cited 2016 Jan 19]. http://www.omicsonline.org/biochemistry-and-analytical-biochemistry-abstract.php?abstract_id=15749

Titel: Time-course of pain and salivary opiorphin release in response to oral capsaicin differ in burning mouth syndrome patients, temporomandibular disorders patients and control subjects
verfasst von: Iva Z. Alajbeg
Ema Vrbanovic
Ivan Alajbeg
Ivan Orabovic
Klara Naka
Antonija Mrla
Yves Boucher
Publikationsdatum: 01.05.2024
Verlag: Springer Berlin Heidelberg
Erschienen in: Clinical Oral Investigations / Ausgabe 5/2024
Print ISSN: 1432-6981
Elektronische ISSN: 1436-3771
DOI: https://doi.org/10.1007/s00784-024-05653-y

Update Zahnmedizin

Bestellen Sie unseren kostenlosen Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Time-course of pain and salivary opiorphin release in response to oral capsaicin differ in burning mouth syndrome patients, temporomandibular disorders patients and control subjects

Abstract

Objectives

Materials and methods

Results

Conclusion

Clinical relevance

Trial registration

Neu im Fachgebiet Zahnmedizin

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

Klinikreform soll zehntausende Menschenleben retten

Darf man die Behandlung eines Neonazis ablehnen?

Ein Drittel der jungen Ärztinnen und Ärzte erwägt abzuwandern

Update Zahnmedizin

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Objectives

Materials and methods

Results

Conclusion

Clinical relevance

Trial registration

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2024

Basal and dentoalveolar transverse parameters in different sagittal and vertical malocclusions in adults: a comparative study

Bleaching efficacy of in-office dental bleaching with different application protocols: a single-blind randomized controlled trial

Conventional and digital maxillary occlusal record for the manufacture of complete-arch implant-supported fixed prostheses: randomized controlled clinical trial

Effects of different primers and colouring solutions on orthodontic bonding: shear bond strength and colour change

Medial sural artery perforator free flap versus radial forearm free flap in oral cavity reconstruction and donor site morbidity

Comparison of different maxillary advancement protocols in patients with unilateral cleft lip and palate: a finite element analysis

Neu im Fachgebiet Zahnmedizin

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

Klinikreform soll zehntausende Menschenleben retten

Darf man die Behandlung eines Neonazis ablehnen?

Ein Drittel der jungen Ärztinnen und Ärzte erwägt abzuwandern

Update Zahnmedizin